Program
HB0043
A development code.
Its studies are mostly in Acne Vulgaris · Hidradenitis Suppurativa, led by Shanghai Huaota Biopharmaceutical.
Furthest: phase 2, since Mar 7, 20253 company-led studies, 2 open or running
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Shanghai Huaota Biopharmaceutical | 32 open or running | phase 2since Mar 7, 2025 | Mar 7, 2025 | none ahead |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Mar 7, 2025First study: phase 2 study in Hidradenitis SuppurativaFirst studyNCT06895499 · 15 planned · China
- May 23, 2025Phase 1 study in HealthyNCT06999083 · 52 enrolled · New Zealand
- Feb 27, 2026Phase 2 study in Acne VulgarisNCT07449156 · 21 planned · China
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07449156Acne Vulgaris · China | 2 | Not yet recruiting | Oct 27, 2026 | 21 |
| NCT06999083Healthy · New Zealand | 1 | Completed | Feb 12, 2026 | 52 |
| NCT06895499Hidradenitis Suppurativa · China | 2 | Recruiting | Jan 30, 2026 | 15 |
How it is read
Names in the registry
- “HB0043”, 5 entries
Codes read as this program: HB0043.
Conditions, from the studies’ own filings
- Acne Vulgaris, 1 study
- Hidradenitis Suppurativa, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.